- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05379725
Mediterranean vs. High-Fermented-Food Diet Adherence on Inflammation in Lupus
October 13, 2022 updated by: University of Florida
Mediterranean vs. High-Fermented-Food Diet Adherence on Inflammation and Disease Activity in Systemic Lupus Erythematosus
This is a 4-month randomized controlled trial to evaluate the feasibility of 'good and very good' adherence to the Mediterranean dietary pattern and to a high-fermented-food diet by individuals with Systemic lupus erythematosus (SLE).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Given the demonstrated beneficial effects of the Mediterranean dietary pattern in autoimmune disease and the potential benefit of a high-fermented-food diet on inflammatory profiles, we aim to determine the feasibility and relative benefit of a Mediterranean dietary pattern versus a high-fermented-food diet on inflammatory markers and clinical outcomes in individuals with SLE.
The primary aim of the study is to evaluate the feasibility of 'good and very good' adherence to the Mediterranean dietary pattern and to a high-fermented-food diet by individuals with SLE.
Secondary aims will determine the effects of the Mediterranean dietary pattern and a high-fermented-food diet on attenuating inflammation and disease activity in individuals with SLE.
This is a 4-month randomized controlled trial with a 1-month baseline of usual diet and 3-month intervention.
Participants will complete the online DHQ III and diet adherence questionnaires monthly.
Blood will be obtained at randomization and at the end of the intervention period for analysis of inflammatory cytokines.
Dietary intake during baseline and intervention will be assessed by 5, ASA 24-h dietary recalls.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wendy J Dahl, PhD
- Phone Number: 3522943707
- Email: wdahl@ufl.edu
Study Contact Backup
- Name: Kaylan Hebert, BS
- Phone Number: 3522639136
- Email: ufnutrition@ifas.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- Recruiting
- University of Florida/UF Health
-
Contact:
- Wendy J Dahl, PhD
- Phone Number: 352-294-3707
- Email: wdahl@ufl.edu
-
Contact:
- Study Coordinator
- Phone Number: 3522639136
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- > 18 years of age
- Able to provide informed consent and undertake study questionnaire completion in English
- Meets SLE diagnostic criteria and is currently under the care of a rheumatologist, nephrologist, or other physician regarding SLE care
- Be willing and able to comply with all the study-related procedures
Exclusion Criteria:
- Pregnant or planning pregnancy within the duration of the interventional study.
- Currently following a vegetarian/vegan diet.
- Allergy/sensitivity to gluten, soy, or cow's milk.
- Self-disclosure of lactose intolerance
- Inability to comply with the study procedures.
- Baseline dietary fiber intake > 30 g/day
- MEDAS score at baseline > 9
- Baseline consumption of > 2 servings per day of fermented foods
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mediterranean diet
Participants will receive diet education on adherence to a Mediterranean dietary pattern.
|
The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.
|
Experimental: Fermented food
Participants will receive diet education on adherence to a high fermented food dietary pattern.
|
Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence - Mediterranean Diet
Time Frame: baseline, month 1, 2 and 3
|
Percent of participants achieving 'good to very good adherence') as assessed by the 14-day Mediterranean diet questionnaire (MEDAS) score
|
baseline, month 1, 2 and 3
|
Adherence - Fermented Food Diet
Time Frame: baseline, month 1, 2, and 3
|
Percent of participants achieving > 5 servings of fermented foods per day
|
baseline, month 1, 2, and 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diet Quality
Time Frame: baseline, month 3
|
Healthy Eating Index 2015 score (0 minimum to 100 maximum).
Higher values indicate better diet quality.
|
baseline, month 3
|
Systemic Lupus Erythematosus Disease Activity
Time Frame: baseline, month 3
|
Systemic Lupus Erythematosus disease activity using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score (0 minimum and 105 maximum, with higher scores representing higher disease activity.
|
baseline, month 3
|
ESR
Time Frame: baseline, month 3
|
Erythrocyte sedimentation rate
|
baseline, month 3
|
hsCRP
Time Frame: baseline, month 3
|
high-sensitivity C-reactive protein
|
baseline, month 3
|
anti-dsDNA
Time Frame: baseline, month 3
|
Anti-double stranded DNA
|
baseline, month 3
|
Cytokine profile
Time Frame: baseline, month 3
|
Cytokines profile e.g., interleukin-18 (IL-18), tumor necrosis factor (TNF), IL-6, IL-2, IL-10
|
baseline, month 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 22, 2022
Primary Completion (Anticipated)
May 4, 2025
Study Completion (Anticipated)
May 4, 2025
Study Registration Dates
First Submitted
May 9, 2022
First Submitted That Met QC Criteria
May 13, 2022
First Posted (Actual)
May 18, 2022
Study Record Updates
Last Update Posted (Actual)
October 17, 2022
Last Update Submitted That Met QC Criteria
October 13, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB202200703
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus Erythematosus, Systemic
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Mediterranean Dietary Pattern
-
Shiraz University of Medical SciencesCompleted
-
University of British ColumbiaCanadian Foundation for Dietetic Research (CFDR)CompletedUlcerative ColitisCanada
-
USDA, Western Human Nutrition Research CenterRecruitingObesity | Body WeightUnited States
-
Universidad de GranadaUniversity of Copenhagen; University of Oxford; Harvard University; University... and other collaboratorsRecruiting
-
Fundacion para la Formacion e Investigacion Sanitarias...Recruiting
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Ohio State University Comprehensive Cancer CenterCompletedMortality | Colorectal Cancer
-
University of TorontoUnknownCardiovascular Diseases | Stroke | Inflammation | Diabetes | Blood Pressure | Coronary Heart Disease | Adiposity | Cardiovascular Risk Factor | Cholesterol; LipidosisCanada
-
Clinica Universidad de Navarra, Universidad de...Ministry of Health, SpainCompleted
-
Emory UniversityCompleted